Cotización Conduit Pharmaceuticals - CDT

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

0.1097

Postura de Compra

0.109

Postura de Venta

0.1098

Volume Operado de la Acción

478,213,923

0.1076 Rango del Día 0.1579

0.0789 Rango de 52 semanas 7.7509

Capitalización de Mercado [m]

10.532M

Precio Anterior

0.0923

Precio de Apertura

0.14465

Hora

400

0.1097

Última hora de negociación

10:01:37

Volumen financiero

US$ 61,117,461

Precio Promedio Ponderado

0.127804

Volumen promedio (3 m)

13,247,434

Acciones en circulación

96,004,699

Rendimiento del Dividendo

Ratio Precio/Utilidad

-267.04

Beneficio por acción (BPA)

-0.06

turnover

Beneficio neto

-6.06M

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto's Thyroiditis. The Company's asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto's Thyroiditis (HT) and Graves' disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto's Thyroiditis and Graves' disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.conduitpharma.com

Sede

Wilmington, Delaware, USA

Fundado

Conduit Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CDT. The last closing price for Conduit Pharmaceuticals was US$0.09. Over the last year, Conduit Pharmaceuticals shares have traded in a share price range of US$ 0.0789 to US$ 7.7509.

Conduit Pharmaceuticals currently has 96,004,699 shares in issue. The market capitalisation of Conduit Pharmaceuticals is US$8.86 million. Conduit Pharmaceuticals has a price to earnings ratio (PE ratio) of -267.04.

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced...

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital...

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial...

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright...

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4...

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.0146	15.3522607781	0.0951	0.1579	0.0826	7148889	0.09040067	CS
4	-0.0003	-0.272727272727	0.11	0.1579	0.0789	7952589	0.10218981	CS
12	-0.0308	-21.9217081851	0.1405	0.1579	0.0789	13247434	0.11360541	CS
26	-2.8203	-96.2559726962	2.93	3.28	0.0789	11920090	0.15402585	CS
52	-1.2003	-91.6259541985	1.31	7.7509	0.0789	6099255	0.18585588	CS
156	-12.4903	-99.1293650794	12.6	12.89	0.0789	5326763	0.21551073	CS
260	-12.4903	-99.1293650794	12.6	12.89	0.0789	5326763	0.21551073	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
WORXSCWorx Corporation	US$ 1.87 (90.82%)	102.31M
CRNCCerence Inc	US$ 5.25 (86.17%)	28.9M
BDRXBiodexa Pharmaceuticals PLC	US$ 6.42 (66.75%)	1.05M
SPAISafe Pro Group Inc	US$ 4.5315 (41.61%)	37.97M
NKGNNKGen Biotech Inc	US$ 0.42 (34.19%)	1.3M
PYXSPyxis Oncology Inc	US$ 2.06 (-46.07%)	8.89M
KURAKura Oncology Inc	US$ 9.90 (-37.77%)	7.26M
BLRXBioLineRx Ltd	US$ 0.357 (-34.52%)	5.51M
SHOTWSafety Shot Inc	US$ 0.1001 (-33.27%)	2.5k
APLMApollomics Inc	US$ 0.1109 (-25.97%)	4.76M
CDTConduit Pharmaceuticals Inc	US$ 0.1106 (19.83%)	475.34M
NVDANVIDIA Corporation	US$ 144.17 (-1.18%)	190.92M
AKTSAkoustis Technologies Inc	US$ 0.104 (19.40%)	179.81M
ELABElevai Labs Inc	US$ 0.0203 (-5.14%)	127.06M
WORXSCWorx Corporation	US$ 1.8799 (91.83%)	102.31M